3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
8
Melanoma
3
Hemangiosarcoma
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Leiomyosarcoma
2
Carcinosarcoma
2
Carcinoma, Endometrioid
2
Vascular Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Synovial
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Liposarcoma
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hemangioendothelioma, Epithelioid
1
Interventions
Doxorubicin
25
Radiotherapy
16
Ifosfamide
14
Trabectedin
10
pazopanib
6
ribociclib
5
pembrolizumab
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Gemcitabine
5
Biopsy
5
palbociclib
4
Radiation
4
Docetaxel
4
Chemotherapy, Adjuvant
4
selinexor
3
liposomal doxorubicin
3
eribulin
3
abemaciclib
3
X-Rays
3
Vincristine
3
Neoadjuvant Therapy
3
Imatinib Mesylate
3
Filgrastim
3
Etoposide
3
Cyclophosphamide
3
toripalimab
2
temsirolimus
2
romidepsin
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liposarcoma
×
durvalumab
×
Sarcoma
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled